ramucirumab,pembrolizumab
eli lilly,merck
['1047p', 'sclc', 'nsclc', 'lcsm,(-blcsm)', '047,(-nct047),(-0.047%)']
#esmo22 results: exploratory analysis of s1800a data evaluating os based on prior response to #checkpoint inhibitor &amp; duration of prev ici treatment. sat, sept 10, 1047p #nsclc #lcsm 
A lung cancer precision medicine trial and unique partnership of @theNCI @CancerResrch @FNIH_org and @SWOG Testing new treatments, including immunotherapies.